For Key Study, UniQure Allowed to Swap Hemophilia Gene Therapies – Xconomy
Xconomy |
For Key Study, UniQure Allowed to Swap Hemophilia Gene Therapies
Xconomy UniQure is trying to get to the finish line for a hemophilia B gene therapy by switching horses mid-race—and it says it has the blessing from regulators to make the unusual change. The company had been testing a gene therapy candidate called AMT-060 … Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for Hemophilia In a PhIII showdown with Spark, uniQure switches out its lead gene … uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 |
